NYU Langone Health

NYU Langone Among First to Enroll Patients In Clinical Trial for COVID-19 Monoclonal Antibody Treatment

Newswise — The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce COVID-19 disease severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.

Eli Lilly and Company announced the trial’s start today, with NYU Grossman School of Medicine among the first centers to enroll patients nationally. The phase 1 clinical trial is designed primarily to measure the safety and side effects of the treatment, called LY-CoV555, in patients hospitalized due to infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).   

Lilly is developing the treatment in collaboration with AbCellera, which used its proprietary drug discovery technology to analyze antibodies from patients that recovered from COVID-19. They sought to find the antibodies which most tightly attached to the virus in places known to block its ability to infect human cells (neutralizing antibodies).

Beyond emergency and supportive care, there are currently no FDA-licensed treatment options for coronavirus disease 2019 (COVID-19), the infection caused SARS-CoV-2.

“We are committed to working with our industry partners to generate scientific evidence from randomized, controlled trials to meet the urgent need for treatments that reduce the severity of COVID-19 disease,” says Mark J. Mulligan, MD, director of the Division of Infectious Diseases and Immunology and director of the Vaccine Center at NYU Langone Health.

“Antibody treatments like the one being studied here hold promise to be effective medical countermeasures against this deadly infection,” says Mulligan, also the Thomas S. Murphy, Sr. Professor in the Department of Medicine at NYU Langone.

Along with Cedars-Sinai Medical Center and Emory University, NYU Langone was chosen as one of the first trial centers because it is known for its clinical trials expertise and capacity to rapidly initiate crucial studies, he adds.

“The world urgently needs medicines that can prevent and treat COVID-19,” says Daniel Skovronsky, MD, PhD, Lilly's chief scientific officer and president of Lilly Research Laboratories. “We’re pleased to partner with NYU Langone and other expert centers around the country on this study and are hopeful we can make a meaningful difference in the fight against COVID-19.”

The current treatment candidate was chosen because it is shaped to interact with the “spike proteins” used by SARS-CoV-2 to attach to human cell surfaces, the first step in invading cells, say the investigators. Viruses must enter cells to multiply and the study treatment is meant to prevent such entry and neutralize the virus. 

Study Details

This randomized, blinded, placebo-controlled, first-in-human study aims to test the safety and tolerability of a single, intravenous dose of LY-CoV555 to hospitalized participants. The study will also look at how long the drug candidate lasts in the body.

Women and men aged 18 to 75 years are eligible for the study if they have moderate to severe COVID-19 illness according to National Institutes of Health (NIH) definitions, but not patients at high risk for respiratory failure, the researchers say. Patients will be excluded for several reasons, including if they require intubation (disease too severe), are pregnant, or have serious bacterial of fungal infections.

The study will proceed in stages, with two patients at first randomized to receive by infusion either the lowest dose of LY-CoV555 or placebo. If the drug is safe in that pair after 24 hours, six additional patients will be treated. If the lowest dose level in those eight patients is well tolerated and safe, a group of eight additional patients would be randomized to receive a slightly higher dose or placebo, with the process repeating for a potential total of up to 32 patients infused over 29 days.                                                                                                                          

If the treatment proves to be safe at each increasing dose, Lilly plans to pivot to the start of a phase II trial, pending regulatory approval, with the potential to test the treatment’s safety in a larger group of patients, including those that have not been hospitalized.  


Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Showing results

110 of 4573